CN114728003B - 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合 - Google Patents

治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合 Download PDF

Info

Publication number
CN114728003B
CN114728003B CN202080076132.6A CN202080076132A CN114728003B CN 114728003 B CN114728003 B CN 114728003B CN 202080076132 A CN202080076132 A CN 202080076132A CN 114728003 B CN114728003 B CN 114728003B
Authority
CN
China
Prior art keywords
capecitabine
administered
pharmaceutically acceptable
acartinib
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080076132.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN114728003A (zh
Inventor
H·德里
B·威利斯
A·布勒赫尔
J·梅特塔尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN114728003A publication Critical patent/CN114728003A/zh
Application granted granted Critical
Publication of CN114728003B publication Critical patent/CN114728003B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202080076132.6A 2019-11-04 2020-10-30 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合 Active CN114728003B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930208P 2019-11-04 2019-11-04
US62/930208 2019-11-04
PCT/EP2020/080493 WO2021089419A1 (en) 2019-11-04 2020-10-30 Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies

Publications (2)

Publication Number Publication Date
CN114728003A CN114728003A (zh) 2022-07-08
CN114728003B true CN114728003B (zh) 2025-01-28

Family

ID=73043259

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080076132.6A Active CN114728003B (zh) 2019-11-04 2020-10-30 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合

Country Status (14)

Country Link
US (1) US20220401442A1 (enExample)
EP (1) EP4054582B1 (enExample)
JP (1) JP7575454B2 (enExample)
KR (1) KR20220098175A (enExample)
CN (1) CN114728003B (enExample)
AU (1) AU2020381240C1 (enExample)
CA (1) CA3158321A1 (enExample)
DK (1) DK4054582T3 (enExample)
ES (1) ES3055126T3 (enExample)
FI (1) FI4054582T3 (enExample)
MX (1) MX2022005250A (enExample)
PL (1) PL4054582T3 (enExample)
PT (1) PT4054582T (enExample)
WO (1) WO2021089419A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230286A2 (en) * 2022-05-25 2023-11-30 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
KR20250105657A (ko) * 2022-11-15 2025-07-08 아스트라제네카 아베 카피바설팁과 베네토클락스의 치료적 조합

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2201012T3 (pl) 2007-10-11 2014-11-28 Astrazeneca Ab Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
EP3689878B1 (en) 2011-07-19 2021-10-06 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
KR20160090903A (ko) * 2013-12-04 2016-08-01 길리애드 사이언시즈, 인코포레이티드 암을 치료하는 방법
CN105979948A (zh) * 2013-12-05 2016-09-28 安塞塔制药公司 Pi3k抑制剂和btk抑制剂的治疗组合
US20180353512A1 (en) * 2015-06-23 2018-12-13 Gilead Sciences, Inc. Combination therapies for treating b-cell malignancies
US20170071962A1 (en) * 2015-09-11 2017-03-16 Acerta Pharma B.V. Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor
CU20180059A7 (es) * 2015-12-17 2018-10-04 Gilead Sciences Inc Compuestos inhibidores de la quinasa de unión a tank
CN107344940B (zh) * 2016-05-06 2020-04-21 广东东阳光药业有限公司 Btk抑制剂及其用途
WO2018097977A1 (en) * 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
WO2019058348A1 (en) * 2017-09-25 2019-03-28 Astrazeneca Ab COMBINATION OF A BTK INHIBITOR AND A CDK9 INHIBITOR TO TREAT CANCER
TW202014184A (zh) * 2018-04-30 2020-04-16 瑞典商阿斯特捷利康公司 用於治療癌症之組合

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Acalabrutinib (ACP-196): a selective secondgeneration BTK inhibitor;Jingjing Wu;Journal of Hematology & Oncology;第9卷(第1期);1-4 *
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL;Tabea Erdmann;Blood;第130卷(第3期);310-322 *

Also Published As

Publication number Publication date
DK4054582T3 (da) 2025-12-01
US20220401442A1 (en) 2022-12-22
WO2021089419A1 (en) 2021-05-14
ES3055126T3 (en) 2026-02-10
PL4054582T3 (pl) 2026-02-16
CA3158321A1 (en) 2021-05-14
JP7575454B2 (ja) 2024-10-29
JP2023501317A (ja) 2023-01-18
EP4054582B1 (en) 2025-09-03
PT4054582T (pt) 2025-12-10
CN114728003A (zh) 2022-07-08
EP4054582A1 (en) 2022-09-14
FI4054582T3 (fi) 2025-12-04
AU2020381240B2 (en) 2023-09-07
AU2020381240A1 (en) 2022-06-23
AU2020381240C1 (en) 2024-02-15
MX2022005250A (es) 2022-06-08
KR20220098175A (ko) 2022-07-11

Similar Documents

Publication Publication Date Title
US10463668B2 (en) Methods of treating and preventing graft versus host disease
JP2023058582A (ja) 神経芽細胞腫の治療における使用のためのオーロラａキナーゼ阻害剤
RU2695228C2 (ru) Прерывистое введение ингибитора mdm2
TW201605454A (zh) 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法
TW201330845A (zh) 胰臟癌及／或膽道癌治療劑
KR20240074779A (ko) 약학적 조성물 및 이의 용도
US20120308562A1 (en) Methods of treating mesothelioma with a pi3k inhibitor compound
CN113194952A (zh) Hdm2-p53相互作用抑制剂和bcl2抑制剂的组合及其治疗癌症的用途
JP7703124B1 (ja) Ｓｅｒｄ投薬レジメンの組み合わせを使用してがんを治療する方法
CN113453671A (zh) 用于治疗癌症的Raf抑制剂和CDK4/6抑制剂的组合疗法
CN114728003B (zh) 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合
KR20220008870A (ko) 노치-활성화 유방암을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물
CN116159062A (zh) 药物组合物及其用途
EP3880207B1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
HK40069821A (en) Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
US20220409582A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
HK40069821B (zh) 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合
TWI671072B (zh) 曲氟尿苷(trifluridine)/替匹拉希(tipiracil)鹽酸鹽、抗腫瘤鉑錯合物及免疫檢查點調節子之間的新穎組合
EA045670B1 (ru) Терапевтические комбинации акалабрутиниба и капивасертиба для лечения в-клеточных злокачественных образований
WO2021048419A1 (en) Combination therapies comprising trametinib for the treatment of cholangiocarcinoma
EP4452275B1 (en) Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers
EP4729061A1 (en) Use of akt inhibitor in preparation of drug for preventing or treating breast cancer
CN120322232A (zh) 喹诺林化合物治疗小细胞肺癌的用途
KR20240056487A (ko) 고형 종양을 치료하기 위한 약제학적 조성물
HK40092504A (zh) 治疗癌症的bcl-2抑制剂和低甲基化剂的组合、其用途和药物组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40069821

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant